Home > Latest > News

Homegrown innovative drugs added to national medical insurance list

Date: 2026-11-18Source: chinadaily.com.cn

Chinese biopharmaceutical company Innovent Biologics' dual-target drug mazdutide has been added to the updated national medical insurance drug list for treating adults with type 2 diabetes, a move expected to make the treatment more affordable for eligible patients.

The drug, marketed as Xinermei, is the first domestically developed dual-target medicine for weight management and blood sugar control to enter the national insurance list, according to the company.

The country unveiled the updated list at a conference on the high-quality development of innovative drugs in Suzhou, Jiangsu province, alongside a separate updated commercial health insurance innovative drug list. Both will take effect on Jan 1, 2027.

Mazdutide works by activating two receptors, GLP-1 and glucagon, to help regulate blood sugar and body weight. Clinical studies involving Chinese patients have shown that the drug can improve blood sugar control, reduce body weight and abdominal fat, and improve other metabolic indicators, according to the company.

The drug received regulatory approval in June 2025 for long-term weight management in adults who are overweight or obese, followed by approval for type 2 diabetes in September that year. Its insurance coverage applies to the diabetes indication, not weight management alone.

The latest insurance list adjustment also covered six other Innovent medicines through new inclusions, expanded indications or renewals.

The changes bring the number of Innovent's marketed medicines covered by national medical insurance to 17 out of 20, spanning oncology, metabolic diseases, autoimmune disorders and eye diseases.

Michael Yu, founder, chairman and CEO of Innovent Biologics, said the expanded insurance coverage would help make innovative medicines more accessible and affordable to Chinese patients.

Another Chinese drugmaker, InnoCare Pharma, said its domestically developed cancer drug zurletrectinib, marketed as Yinuoxin, had also been included in the national insurance list.

The drug, approved in December 2025, is used to treat adults and adolescents aged 12 and above with solid tumors carrying NTRK gene fusions, regardless of where the cancer originated.

Zurletrectinib is China's first domestically developed next-generation TRK inhibitor to gain regulatory approval, according to the company. It works by blocking proteins that drive the growth of tumors carrying NTRK gene fusions.

In a pivotal clinical study, the drug achieved an overall response rate of 89.1 percent and a disease control rate of 96.4 percent, according to InnoCare.

Its inclusion in the insurance list is expected to improve access to targeted treatment for patients with these relatively rare genetic alterations across different types of cancer.